Company intelligence / Profile preview

Lumaegis

Austin, Texas, United States

Ownership: Private
Development stage: Other

Overview

Lumaegis has built the first pre-production units of RadBox—a novel LED-based sterilization device—which has demonstrated rapid 6-log pathogen kill in under 6 minutes in pre-clinical testing. The RadBox received FDA De Novo designation in July 2024, with full clearance pending; anticipated first sales are in 2026[1][2].

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Undisclosed global industry partner and investor in the disinfection/sterilization space[2]

Beyond the preview

Go deeper on Lumaegis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumaegis.

Explore the full profile